Type(s) of biological therapy-Trastuzumab (Herceptin) Posts on Medivizor
Navigation Menu

Type(s) of biological therapy-Trastuzumab (Herceptin) Posts on Medivizor

Evaluating the final effectiveness and safety outcomes of neratinib in patients with early stage HER2+/HR+ breast cancer.

Evaluating the final effectiveness and safety outcomes of neratinib in patients with early stage HER2+/HR+ breast cancer.

Posted by on Apr 4, 2021 in Breast cancer | 0 comments

In a nutshell This study reported the final effectiveness and safety outcomes of neratinib treatment in patients with early-stage HER2+/HR+ breast cancer. The data showed that neratinib significantly improved invasive disease-free survival in these patients who initiated treatment within 1 year of trastuzumab-based therapy. Some background...

Read More

Is heart monitoring needed in patients with HER2-positive metastatic breast cancer using trastuzumab?

Is heart monitoring needed in patients with HER2-positive metastatic breast cancer using trastuzumab?

Posted by on Feb 20, 2021 in Breast cancer | 0 comments

In a nutshell This article looked at the occurrence of heart-related side effects in patients with HER2-positive metastatic breast cancer (mBC) receiving trastuzumab (Herceptin). The authors found that non-smoking patients with a good heart function before receiving treatment have a low risk of heart toxicity (HT) after 4 years...

Read More

Lisinopril versus carvedilol to prevent trastuzumab-related heart problems in patients with breast cancer.

Posted by on Jun 23, 2019 in Breast cancer | 0 comments

In a nutshell This study wanted to find out if lisinopril (Zestril) or carvedilol (Coreg) can help prevent heart problems in patients with HER2 positive breast cancer who are treated with trastuzumab (Herceptin). The study found that both of these medications helped reduce the chance of heart problems in these patients if they were also being...

Read More

Adding anthracyclines or carboplatin to standard treatment of breast cancer

Posted by on Nov 17, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to find out which medication is better for treating HER-2 positive breast cancer, a class of medicines called anthracyclines plus trastuzmab (Herceptin) and pertuzmab (Perjeta), or carboplatin (Paraplatin) plus trastuzmab and pertuzmab. The study found that both medications worked equally as well as each other, but the...

Read More

Addition of traustuzumab to adjuvant anthracycline and taxane based chemotherapy does not worsen long-term heart function or health related quality of life.

Posted by on Dec 9, 2017 in Breast cancer | 0 comments

In a nutshell This study set out to evaluate heart function in patients who received traustuzumab with anthracycline and taxane–based chemotherapy. This study concluded that, in patients without heart disease at baseline, adding traustuzumab to adjuvant anthracycline and taxane–based...

Read More

ASCO 2017: Breast Cancer Research News

Posted by on Sep 28, 2017 in Breast cancer | 0 comments

Video information: Breast cancer experts gathered at the 2017 American Society of Clinical Oncology meeting to discuss developments in research and treatment. Patient Power founder, Andrew Schorr, was on-site in Chicago and interviewed Dr. Julie Gralow, Director of Breast Medical Oncology at the Seattle Cancer Care Alliance. Dr. Gralow shares...

Read More

The effectiveness and cardiac safety of CMF plus trastuzumab in HER2-positive metastatic breast cancer

Posted by on Apr 13, 2017 in Breast cancer | 0 comments

In a nutshell This study investigated the safety and effectiveness of treatment with combination cyclophosphamide (Cytoxan), methotrexate (Otrexup) and 5-fluoruoracil (Efudex) (CMF) plus trastuzumab (Herceptin) in HER2-positive metastatic breast cancer (MBC, cancer that has spread beyond the breast) patients. CMF plus trastuzumab (CMF+T) was found to...

Read More

How does hormone receptor status affect patient response to trastuzumab therapy in metastatic breast cancer

Posted by on Mar 20, 2017 in Breast cancer | 0 comments

In a nutshell This study investigated the clinical factors that influence patient response to trastuzumab (Herceptin) therapy in human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (MBC). Hormone receptor (HR) status was found to be a possible predictor of a strong response to trastuzumab-based therapy. Some background...

Read More

Cardiac events after treatment with trastuzumab

Posted by on Feb 29, 2016 in Breast cancer | 0 comments

In a nutshell This study investigated the rate and outcome of trastuzumab (Herceptin) associated cardiac (heart) dysfunction in patients after 1 or 2 years of therapy. The study concluded that for patients treated with adjuvant trastuzamab, the occurrence of cardiac events remained low and that these cardiac events were mostly reversible after...

Read More

Does trastuzumab increase the risk of infection?

Posted by on Aug 9, 2015 in Breast cancer | 0 comments

In a nutshell The authors aimed to determine whether or not the breast cancer treatment trastuzumab (Herceptin) increased the risk of developing certain infections. Some background Human epidermal growth factor receptor positive (HER2+) breast cancers are dependent on the HER2 protein for growth. It is often targeted with a particular...

Read More